Emergent BioSolutions (EBS) Proxy filing summary

Executive summary

• Requesting shareholder approval for a new stock plan due to depletion of existing share reserve, aiming to maintain a competitive equity program.

• Recent turnaround efforts led to improved profitability, adjusted EBITDA rising from negative in 2023 to $183 million in 2024 and $205 million in 2025.

• Share price increased approximately 450% since February 2024, reflecting early progress in the turnaround.

• Net debt reduced by $373 million from year-end 2023 to year-end 2025, with leverage improving from 9.9x to 1.9x.

• Additional share reserve is expected to support about one year of grants, not a multi-year stockpile.

Voting matters and shareholder proposals

• Proposal seeks approval for a 5.0 million-share increase to the equity plan, with 2,043,910 contingent 2026 awards forfeited if not approved.

• Only 453,248 shares remain available under the current plan as of March 6, 2026.

• If proposal fails, company would need to rely more on cash compensation, potentially impacting financial performance and investment flexibility.

Executive compensation and say-on-pay

• CEO's 2025 equity mix split between stock options and PSUs tied to adjusted EBITDA; 2026 award is 25% options, 25% RSUs, 50% PSUs.

• PSU outcomes show downside risk: 2021-2023 cycle paid out at 0%, 2023-2025 at 25% of target.

• Plan includes no evergreen provision, no repricing without shareholder approval, no discounted options, no dividends on unvested awards, and a $1 million non-employee director cap.